Final stretch for the FMD Fierce 15

Folks, we wanted to remind you to mark your calendars for Oct. 2. On that day, we'll be publishing our first annual special report recognizing the FierceMedicalDevices Fierce 15, a roundup of some of the sharpest, most innovative, privately-owned device and diagnostics companies out there. (We follow in the footsteps of the annual FierceBiotech Fierce 15, which published on Wednesday. You can read about this year's visionary crop of biotech winners here.

All of the FMD Fierce 15 have attracted serious investor interest in what has become an eternally tough venture capital climate, and they are supported by energetic, innovative leadership. And their devices and diagnostics are poised to significantly advance the standard of care in their own specific sector.

Right now, we are gearing up to notify our winners, but they'll be under wraps until Oct. 2. In addition to publishing the special report, we'll also announce the FMD Fierce 15 that afternoon at the AdvaMed 2012 conference in Boston. Co-editor Damian Garde (email | Twitter) and I will both be there, and FierceMedicalDevices will also be manning a fantastic booth. We're looking forward to seeing you all at the convention, so please come by to meet with us, and the FMD team. More to come. -- Mark Hollmer (email | Twitter)

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.